Colin Freund
Private Equity Investor bei Delin Ventures Ltd.
Profil
Colin Freund is currently a Partner at Delin Ventures Ltd.
He previously served as the Chief Executive Officer at QUE Oncology, Inc. in 2017.
Colin also held the position of Chief Executive Officer at Modra Pharmaceuticals BV.
From 2013 to 2015, he was the Chief Business Officer at Transgene SA. Additionally, Colin served as the Chief Business Officer & Senior Vice President at Agennix AG.
He holds an MBA from Stanford University and an undergraduate degree from the University of Cambridge.
Aktive Positionen von Colin Freund
| Unternehmen | Position | Beginn |
|---|---|---|
Delin Ventures Ltd.
 Delin Ventures Ltd. Investment ManagersFinance Delin Ventures Ltd. (Delin Ventures) is a venture capital firm founded in 2013 by Igor Linshits. The firm headquartered in London, United Kingdom. | Private Equity Investor | 01.10.2023 |
Ehemalige bekannte Positionen von Colin Freund
| Unternehmen | Position | Ende |
|---|---|---|
QUE Oncology, Inc.
 QUE Oncology, Inc. Pharmaceuticals: MajorHealth Technology QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA. | Vorstandsvorsitzender | 07.06.2017 |
| TRANSGENE | Corporate Officer/Principal | 01.12.2015 |
Modra Pharmaceuticals BV
 Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Modra Pharmaceuticals BV designs and develops oral formulations of commonly used anti-cancer drugs. It is a clinical-stage company which develops series of oral formulations of existing IV anticancer drugs which reduce the side effects common to IV formulations, thereby improving patient convenience. The company was founded in June 2010 and is headquartered in Amsterdam, the Netherlands. | Vorstandsvorsitzender | - |
| AGENNIX AG | Corporate Officer/Principal | - |
Ausbildung von Colin Freund
| University of Cambridge | Undergraduate Degree |
| Stanford University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TRANSGENE | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Agennix AG
 Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany. | Health Technology |
QUE Oncology, Inc.
QUE Oncology, Inc. Pharmaceuticals: MajorHealth Technology QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA. | Health Technology |
Modra Pharmaceuticals BV
Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Modra Pharmaceuticals BV designs and develops oral formulations of commonly used anti-cancer drugs. It is a clinical-stage company which develops series of oral formulations of existing IV anticancer drugs which reduce the side effects common to IV formulations, thereby improving patient convenience. The company was founded in June 2010 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Delin Ventures Ltd.
Delin Ventures Ltd. Investment ManagersFinance Delin Ventures Ltd. (Delin Ventures) is a venture capital firm founded in 2013 by Igor Linshits. The firm headquartered in London, United Kingdom. | Finance |
